MP CARDIOFLOW-B (02160) shares climbed more than 13%, trading at HK$1.19 as of the latest update, representing a 13.33% increase with a turnover of HK$1.83 million.

On July 25, the company announced that its AnchorMan® Left Atrial Appendage Occluder and guiding system had received marketing approval in Australia. Additionally, the new-generation SmartView Connect™ V15108 Bluetooth remote monitoring system was approved for sale in both Europe and Australia.

With this successful entry into the Australian market, the left atrial appendage occluder from MP CARDIOFLOW-B now covers China (including Hong Kong and Macau), Europe, Latin America, and Australia. The company noted that Europe and Australia are major global healthcare markets with high entry barriers and strict regulatory requirements. These approvals signify further recognition from premium international markets for MP CARDIOFLOW-B's solutions.

As several core products continue to gain traction in mainstream global markets, MP CARDIOFLOW-B's global expansion in the structural heart disease and heart rhythm management fields is accelerating.